Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma  

作　　者：Min Yao Rong-Fei Fang Qun Xie Min Xu Wen-Li Sai Deng-Fu Yao 

机构地区：[1]Department of Immunology,Medical School of Nantong University and Research Center of Clinical Medicine,The Affiliated Hospital of Nantong University,Nantong 226001,Jiangsu Province,China [2]Department of Gastroenterology,The Affiliated Hospital of Nantong University,Nantong 226001,Jiangsu Province,China [3]Department of Infectious Diseases,Haian People’s Hospital,Haian 226600,Jiangsu Province,China [4]Research Center of Clinical Medicine,The Affiliated Hospital of Nantong University,Nantong 226001,Jiangsu Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2024年第6期2350-2361,共12页世界胃肠肿瘤学杂志（英文版）（电子版）

基　　金：Supported by National Natural Science Foundation of China,No.81673241 and No.31872738;Nantong Infectious Disease Alliance Fund,No.202308001.

摘　　要：The prevention and early diagnosis of liver cancer remains a global medical challenge.During the malignant transformation of hepatocytes,a variety of oncogenic cellular signalling molecules,such as novel high mobility group-Box 3,angiopoietin-2,Golgi protein 73,glypican-3,Wnt3a(a signalling molecule in the Wnt/β-catenin pathway),and secretory clusterin,can be expressed and secreted into the blood.These signalling molecules are derived from different signalling pathways and may not only participate in the malignant transformation of hepatocytes but also become early diagnostic indicators of hepatocarcinogenesis or specific targeted molecules for hepatocellular carcinoma therapy.This article reviews recent progress in the study of several signalling molecules as sensitive biomarkers for monitoring hepatocarcinogenesis.

关 键 词：HEPATOCARCINOGENESIS Cell signals Specific biomarkers Early diagnosis 

分 类 号：R735.7[医药卫生—肿瘤]